• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Lantern Pharma Inc. (Amendment)

    2/14/24 4:05:49 PM ET
    $LTRN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $LTRN alert in real time by email
    SC 13G/A 1 formsc13ga.htm

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 13G/A

    (Amendment No. 1)

     

    Under the Securities Exchange Act of 1934

     

    Lantern Pharma Inc.

    (Name of Issuer)

     

    Common Stock, $0.0001 par value per share

    (Title of Class of Securities)

     

    51654W101

    (CUSIP Number)

     

    December 31, 2023

    (Date of Event which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ☐ Rule 13d-1(b)

     

    ☒ Rule 13d-1(c)

     

    ☐ Rule 13d-1(d)

     

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes)

     

     

     

     
     

     

    CUSIP No. 51654W101

     

    1.

    NAMES OF REPORTING PERSONS

    ProPhase Labs, Inc.

     

     
    2.

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)

    (a) ☐ (b) ☐

     

     
    3.

    SEC USE ONLY

     

    4.

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware

     

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH
    5.

    SOLE VOTING POWER

    631,195

    6.

    SHARED VOTING POWER

    0

    7.

    SOLE DISPOSITIVE POWER

    631,195

    8.

    SHARED DISPOSITIVE POWER

    0

    9.

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    631,195

    10.

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (see instructions) ☐

     

    11.

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    5.8% (1)

    12.

    TYPE OF REPORTING PERSON (see instructions)

    CO

     

    (1) Based on 10,869,040 shares outstanding as of November 3, 2023 according to the quarterly report on Form 10-Q filed by the Issuer with the Securities and Exchange Commission on November 8, 2023.

     

     
     

     

    Item 1.

     

    (a) Name of Issuer:

     

    Lantern Pharma Inc. (the “Issuer”)

     

    (b) Address of Issuer’s Principal Executive Offices:

     

    1920 McKinney Avenue, 7th Floor Dallas, Texas 75201

     

    Item 2.

     

    (a)-(c) Name, Address and Citizenship of Reporting Persons

     

    ProPhase Labs, Inc.

    711 Stewart Ave, Suite 200

    Garden City, New York 11530

    Place of Incorporation: Delaware

     

    (d) Title of Class of Securities

     

    Common Stock, $0.0001 par value per share (“Common Stock”)

     

    (e) CUSIP Number

    51654W101

     

    Item 3. If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

     

    Not applicable.

     

    Item 4. Ownership.

     

    (a) Amount Beneficially Owned:

     

    Please refer to items 5-9 of the cover pages attached hereto.

     

    (b) Percent of Class

     

    Please refer to item 11 of the cover pages attached hereto

     

    (c) Number of shares as to which such person has:

     

    Please refer to items 5-8 of the cover pages attached hereto

     

    Item 5. Ownership of Five Percent or Less of a Class.

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following: ☐

     

    Item 6. Ownership of More than Five Percent on Behalf of Another Person.

     

    Not applicable.

     

     
     

     

    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company.

     

    Not applicable.

     

    Item 8. Identification and Classification of Members of the Group.

     

    Not applicable.

     

    Item 9. Notice of Dissolution of Group.

     

    Not applicable.

     

    Item 10. Certification.

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

     

     
     

     

    SIGNATURES

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Date: February 14, 2024 PROPHASE LABS, INC.
         
      By: /s/ Ted Karkus
      Name: Ted Karkus
      Title: Chairman of the Board and Chief Executive Officer

     

     

    Get the next $LTRN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $LTRN

    DatePrice TargetRatingAnalyst
    3/11/2022$34.00 → $36.00Buy
    HC Wainwright & Co.
    11/2/2021$32.00 → $34.00Buy
    HC Wainwright & Co.
    10/7/2021$32.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $LTRN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Lantern Pharma Confirms Panna Sharma Continues to Serve as President and CEO; Alerts Investors to False Third-Party Report

    Lantern Pharma Inc. (NASDAQ:LTRN) ("Lantern" or the "Company"), an AI‑driven, clinical‑stage oncology company leveraging its proprietary RADR® platform to transform the cost and timeline of cancer drug development, today issued the following statement in response to an article published earlier today on an unverified third‑party website. The third‑party article incorrectly claimed that Panna Sharma has stepped down as President and Chief Executive Officer of Lantern. This claim is false, entirely without basis, and appears designed to mislead investors. No such communication has been issued by the Company or its Board of Directors. Mr. Sharma continues to serve as President, Chief Execu

    3/27/26 7:23:00 PM ET
    $LTRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Lantern Pharma and Starlight Therapeutics Announce FDA Clearance of IND for a Planned Phase 1 Pediatric CNS Cancer Trial of STAR-001

    The Planned Multicenter Phase 1 Trial Will Evaluate STAR-001 as Monotherapy and in Combination with Spironolactone in Children with Relapsed or Refractory CNS Malignancies, Including ATRT, DIPG, GBM, Medulloblastoma, and Ependymoma Lantern Pharma Inc. (NASDAQ:LTRN) and its CNS-oncology focused wholly owned subsidiary Starlight Therapeutics today announced that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for STAR-001 in a planned Phase 1 pediatric clinical trial (IND No. 179145). STAR-001 is a precision oncology compound whose CNS and pediatric CNS indications were initially identified using Lantern's proprietary RADR® AI platfor

    3/27/26 7:29:00 AM ET
    $LTRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Lantern Pharma to Report Fourth Quarter and Fiscal Year 2025 Operating & Financial Results on March 30th, 2026 at 4:30 p.m. ET

    Webcast to be held Monday, March 30th, 4:30 p.m. ET, register for the webcast here, or at the link provided below.  Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence ("AI") company developing targeted and transformative cancer therapies using its proprietary RADR® AI and machine learning ("ML") platform with multiple clinical stage drug programs, today announced that it will host its fourth quarter and fiscal year 2025 operating and financial results webcast on Monday, March 30, 4:30 p.m. Eastern Time / 1:30 p.m. Pacific Time. Management intends to discuss the operating and financial results for the fourth quarter and fiscal year ended December 31, 2025 and provide guidan

    3/23/26 4:30:00 PM ET
    $LTRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LTRN
    SEC Filings

    View All

    Lantern Pharma Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Lantern Pharma Inc. (0001763950) (Filer)

    1/23/26 7:31:05 AM ET
    $LTRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Lantern Pharma Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Lantern Pharma Inc. (0001763950) (Filer)

    11/13/25 8:30:56 AM ET
    $LTRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by Lantern Pharma Inc.

    10-Q - Lantern Pharma Inc. (0001763950) (Filer)

    11/12/25 4:17:11 PM ET
    $LTRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LTRN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Silberstein David S.

    4 - Lantern Pharma Inc. (0001763950) (Issuer)

    1/13/26 4:05:08 PM ET
    $LTRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Chandru Vijay

    4 - Lantern Pharma Inc. (0001763950) (Issuer)

    1/13/26 4:05:11 PM ET
    $LTRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Schalop Lee Troy

    4 - Lantern Pharma Inc. (0001763950) (Issuer)

    1/13/26 4:05:09 PM ET
    $LTRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LTRN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    HC Wainwright & Co. reiterated coverage on Lantern Pharma with a new price target

    HC Wainwright & Co. reiterated coverage of Lantern Pharma with a rating of Buy and set a new price target of $36.00 from $34.00 previously

    3/11/22 6:29:59 AM ET
    $LTRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    HC Wainwright & Co. reiterated coverage on Lantern Pharma with a new price target

    HC Wainwright & Co. reiterated coverage of Lantern Pharma with a rating of Buy and set a new price target of $34.00 from $32.00 previously

    11/2/21 6:34:51 AM ET
    $LTRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    HC Wainwright & Co. initiated coverage on Lantern Pharma with a new price target

    HC Wainwright & Co. initiated coverage of Lantern Pharma with a rating of Buy and set a new price target of $32.00

    10/7/21 8:16:17 AM ET
    $LTRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LTRN
    Leadership Updates

    Live Leadership Updates

    View All

    Lantern Pharma Announces Appointment of Dr. Lee Schalop to Board of Directors

    Seasoned Biotech Executive & Wall Street Analyst Brings Deep Expertise in Precision Neurooncology, Biopharma Partnering and Clinical Development Lantern Pharma Inc. (NASDAQ:LTRN), a clinical-stage biopharmaceutical company using artificial intelligence, machine learning and genomic data to transform the cost, pace and timeline of oncology drug discovery and development, today announced the appointment of Lee T. Schalop, MD, to its Board of Directors. Dr. Schalop brings over two decades of combined experience in biotechnology leadership and financial markets, with particular expertise in precision neurooncology and clinical development. Most notably, he co-founded and was a key member

    7/28/25 8:00:00 AM ET
    $CMRX
    $LTRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Lantern Pharma Expands Management Team with Appointment of Two Leading Industry Executives to Support Clinical and Manufacturing Initiatives

    DALLAS, Sept. 2, 2021 /PRNewswire/ -- Lantern Pharma (NASDAQ:LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("A.I.") platform to transform the cost, pace, and timeline of oncology drug discovery and development, today announced the addition of two senior industry executives to support the Company's clinical and manufacturing initiatives. Dr. Harry Kochat has been appointed Senior Director of Chemistry, Manufacturing and Controls (CMC) and Manufacturing Quality Affairs, where his responsibilities will include oversight of drug candidate manufacturing and quality control. Darlene Bunpian, MPH has been appointed Clinical Trial Project Manag

    9/2/21 8:59:00 AM ET
    $LTRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LTRN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13D/A filed by Lantern Pharma Inc. (Amendment)

    SC 13D/A - Lantern Pharma Inc. (0001763950) (Subject)

    3/1/24 4:10:40 PM ET
    $LTRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Lantern Pharma Inc. (Amendment)

    SC 13G/A - Lantern Pharma Inc. (0001763950) (Subject)

    2/14/24 4:05:49 PM ET
    $LTRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D/A filed by Lantern Pharma Inc. (Amendment)

    SC 13D/A - Lantern Pharma Inc. (0001763950) (Subject)

    12/1/23 6:02:25 AM ET
    $LTRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LTRN
    Financials

    Live finance-specific insights

    View All

    Lantern Pharma to Report Fourth Quarter and Fiscal Year 2025 Operating & Financial Results on March 30th, 2026 at 4:30 p.m. ET

    Webcast to be held Monday, March 30th, 4:30 p.m. ET, register for the webcast here, or at the link provided below.  Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence ("AI") company developing targeted and transformative cancer therapies using its proprietary RADR® AI and machine learning ("ML") platform with multiple clinical stage drug programs, today announced that it will host its fourth quarter and fiscal year 2025 operating and financial results webcast on Monday, March 30, 4:30 p.m. Eastern Time / 1:30 p.m. Pacific Time. Management intends to discuss the operating and financial results for the fourth quarter and fiscal year ended December 31, 2025 and provide guidan

    3/23/26 4:30:00 PM ET
    $LTRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Lantern Pharma Reports Third Quarter 2025 Financial Results and Provides Business Updates

    Transformational Quarter Marked by Clinical Validation, Regulatory Progress, and Strategic Momentum in Commercial AI Platform Launch LP-184 Phase 1a clinical trial results demonstrate all primary endpoints achieved with 48% clinical benefit rate in evaluable cancer patients at or above therapeutic dose threshold; marked tumor reductions observed in patients with DNA damage repair mutations including CHK2, ATM, and STK11/KEAP1 alterations. FDA Type C meeting completed, providing regulatory guidance and pathway clarity for Starlight Therapeutics' planned pediatric CNS cancer trial in Atypical Teratoid Rhabdoid Tumor (ATRT) and confirming spironolactone combination strategy. LP-300 pr

    11/13/25 8:30:00 AM ET
    $LTRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Lantern Pharma to Report Third Quarter 2025 Operating & Financial Results on November 13th, 2025 at 9:00 a.m. ET

    Webcast to be held Thursday, November 13th, 9:00 a.m. ET, register for the webcast here, or at the link provided below. Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence ("AI") company developing targeted and transformative cancer therapies using its proprietary RADR® AI and machine learning ("ML") platform with multiple clinical stage drug programs, today announced that it will host its third quarter 2025 operating and financial results webcast on Thursday, November 13, 9:00 a.m. Eastern Time / 6:00 a.m. Pacific Time. Management intends to discuss the operating and financial results for the third quarter ended September 30, 2025 and provide guidance on upcoming milestones,

    11/6/25 8:00:00 AM ET
    $LTRN
    Biotechnology: Pharmaceutical Preparations
    Health Care